Vupanorsen

Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

Product Specifications

CAS Number

[2097587-62-5]

Product Name Alternative

IONIS ANGPT-L3Rx; ISIS 703802

UNSPSC

12352208

Target

ANGPTL

Type

Oligonucleotides

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/vupanorsen.html

Purity

92.29

Solubility

10 mM in H2O

Smiles

[Vupanorsen]

Molecular Weight

8665.50

References & Citations

[1]Bergmark BA, Marston NA, Bramson CR, et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145 (18) :1377-1386.|[2]Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41 (40) :3936-3945.